Trial Profile
Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) Previously Treated With Imatinib.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2017
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Novartis
- 21 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 May 2010 New trial record